This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Preliminary Report

MARTIN ZWERLING, M.D.

AMA Arch Otolaryngol. 1955;62(2):157-158.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

For over a hundred years chemists have been attempting to use the powerful germicidal effect of chlorine as an agent in controlling infection. Recently a new group of agents have been developed, consisting of modified buffered hypochlorous acid derivatives, which appear to yield their active chlorine almost quantitatively as hypochlorous acid. Chemically they can be classified as monoxychlorosene^* derivatives. This paper is a preliminary report of the use of Clorpactin WCS-90 in otolaryngology.

CHEMISTRY

Clorpactin is produced in various strengths, consisting of white, water-soluble powders or granules, whose dilute solutions are powerful germicides, fungicides, and virucides, yet are nontoxic and nonirritating when used in therapeutic dosages. These hypochlorous acid derivatives form dilute solutions with pH's varying from a highly acid 4.2 to substantially neutral, and are highly buffered. They are excellent oxidizing agents, effective deodorizers, and exhibit pronounced wetting, penetrating, and detergent properties. The grade of Clorpactin used in this . . . [Full Text PDF of this Article]

Author Affiliations
Bay Shore, N. Y.

From the Department of Otolaryngology, Southside Hospital.

Footnotes
Submitted for publication March 16, 1955.

Clorpactin. The chemical data were obtained through the courtesy of the Guardian Chemical Corporation (Long Island City, N. Y.), which also supplied the material for clinical trial.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?